Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(9):1302–1308. doi: 10.1038/bjc.1997.221

MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.

M Higashiyama 1, O Doi 1, K Kodama 1, H Yokouchi 1, T Kasugai 1, S Ishiguro 1, K Takami 1, T Nakayama 1, I Nishisho 1
PMCID: PMC2228229  PMID: 9155050

Abstract

MDM2 is an oncoprotein that inhibits p53 tumour-suppressor protein. Amplification of the MDM2 gene and overexpression of its protein have been observed in some human malignancies, and these abnormalities have a role in tumorigenesis through inactivation of p53 function. To determine the clinicopathological and prognostic value of MDM2 abnormalities in non-small-cell lung cancer (NSCLC), MDM2 gene amplification and its protein expression status were analysed in surgically resected materials. MDM2 gene amplification was detected in only 2 (7%) of the 30 tested patients. MDM2 protein was found immunohistochemically in a total of 48 (24%) of the 201 patients. MDM2 protein was slightly frequently observed in patients with adenocarcinoma, but its presence or absence was not associated with clinicopathological factors such as T-factor, N-factor, stage, tumour size, differentiation or p53 protein status. Overall, MDM2-positive patients tended to have a better prognosis (P = 0.062). In particular, among immunohistochemically p53-negative patients (n = 110), those with positive MDM2 protein expression showed significantly better prognosis (P = 0.039) and, in a multivariate analysis, MDM2 protein status was a favourable prognostic factor (P = 0.037). In contrast, among p53-positive patients (n = 91), there was no difference in prognosis depending on MDM2 protein status. Thus, in the NSCLC patients studied, MDM2 gene amplification was a minor event, but expression of its protein, which was often observed immunohistochemically, was a favourable prognostic marker, especially among patients without p53 protein accumulation. Further study is needed to determine how MDM2 protein expression results in a better prognosis.

Full text

PDF
1302

Images in this article

1303Figure 1
on p.1303
1303Figure 2
on p.1303

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bueso-Ramos C. E., Yang Y., deLeon E., McCown P., Stass S. A., Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993 Nov 1;82(9):2617–2623. [PubMed] [Google Scholar]
  2. Cahilly-Snyder L., Yang-Feng T., Francke U., George D. L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet. 1987 May;13(3):235–244. doi: 10.1007/BF01535205. [DOI] [PubMed] [Google Scholar]
  3. Cattoretti G., Becker M. H., Key G., Duchrow M., Schlüter C., Galle J., Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):357–363. doi: 10.1002/path.1711680404. [DOI] [PubMed] [Google Scholar]
  4. Fakharzadeh S. S., Trusko S. P., George D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991 Jun;10(6):1565–1569. doi: 10.1002/j.1460-2075.1991.tb07676.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Flørenes V. A., Maelandsmo G. M., Forus A., Andreassen A., Myklebost O., Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst. 1994 Sep 7;86(17):1297–1302. doi: 10.1093/jnci/86.17.1297. [DOI] [PubMed] [Google Scholar]
  6. Foulkes W. D., Stamp G. W., Afzal S., Lalani N., McFarlane C. P., Trowsdale J., Campbell I. G. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer. 1995 Oct;72(4):883–888. doi: 10.1038/bjc.1995.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gudas J. M., Nguyen H., Klein R. C., Katayose D., Seth P., Cowan K. H. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res. 1995 Jan;1(1):71–80. [PubMed] [Google Scholar]
  8. Habuchi T., Kinoshita H., Yamada H., Kakehi Y., Ogawa O., Wu W. J., Takahashi R., Sugiyama T., Yoshida O. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst. 1994 Sep 7;86(17):1331–1335. doi: 10.1093/jnci/86.17.1331. [DOI] [PubMed] [Google Scholar]
  9. Haines D. S., Landers J. E., Engle L. J., George D. L. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol. 1994 Feb;14(2):1171–1178. doi: 10.1128/mcb.14.2.1171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ikenberg H., Matthay K., Schmitt B., Bauknecht T., Kiechle-Schwarz M., Göppinger A., Pfleiderer A. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Cancer. 1995 Jul 1;76(1):57–66. doi: 10.1002/1097-0142(19950701)76:1<57::aid-cncr2820760108>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  11. Keleti J., Quezado M. M., Abaza M. M., Raffeld M., Tsokos M. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol. 1996 Jul;149(1):143–151. [PMC free article] [PubMed] [Google Scholar]
  12. Kessis T. D., Slebos R. J., Han S. M., Shah K., Bosch X. F., Muñoz N., Hedrick L., Cho K. R. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol. 1993 Nov;143(5):1398–1405. [PMC free article] [PubMed] [Google Scholar]
  13. Landers J. E., Haines D. S., Strauss J. F., 3rd, George D. L. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene. 1994 Sep;9(9):2745–2750. [PubMed] [Google Scholar]
  14. Leach F. S., Tokino T., Meltzer P., Burrell M., Oliner J. D., Smith S., Hill D. E., Sidransky D., Kinzler K. W., Vogelstein B. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993 May 15;53(10 Suppl):2231–2234. [PubMed] [Google Scholar]
  15. Lianes P., Orlow I., Zhang Z. F., Oliva M. R., Sarkis A. S., Reuter V. E., Cordon-Cardo C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst. 1994 Sep 7;86(17):1325–1330. doi: 10.1093/jnci/86.17.1325. [DOI] [PubMed] [Google Scholar]
  16. Marchetti A., Buttitta F., Girlando S., Dalla Palma P., Pellegrini S., Fina P., Doglioni C., Bevilacqua G., Barbareschi M. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol. 1995 Jan;175(1):31–38. doi: 10.1002/path.1711750106. [DOI] [PubMed] [Google Scholar]
  17. Marchetti A., Buttitta F., Pellegrini S., Merlo G., Chella A., Angeletti C. A., Bevilacqua G. mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol. 1995 Jun;4(2):93–97. doi: 10.1097/00019606-199506000-00004. [DOI] [PubMed] [Google Scholar]
  18. Matsumura T., Yoshihama Y., Kimura T., Shintani S., Alcalde R. E. p53 and MDM2 expression in oral squamous cell carcinoma. Oncology. 1996 Jul-Aug;53(4):308–312. doi: 10.1159/000227578. [DOI] [PubMed] [Google Scholar]
  19. McCann A. H., Kirley A., Carney D. N., Corbally N., Magee H. M., Keating G., Dervan P. A. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer. 1995 May;71(5):981–985. doi: 10.1038/bjc.1995.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nakayama T., Toguchida J., Wadayama B., Kanoe H., Kotoura Y., Sasaki M. S. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer. 1995 Oct 20;64(5):342–346. doi: 10.1002/ijc.2910640511. [DOI] [PubMed] [Google Scholar]
  21. Ofner D., Maier H., Riedmann B., Holzberger P., Nogler M., Tötsch M., Bankfalvi A., Winde G., Böcker W., Schmid K. W. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. Clin Mol Pathol. 1995 Feb;48(1):M12–M16. doi: 10.1136/mp.48.1.m12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992 Jul 2;358(6381):80–83. doi: 10.1038/358080a0. [DOI] [PubMed] [Google Scholar]
  23. Qian W., Hu L. F., Chen F., Wang Y., Magnusson K. P., Kashuba E., Klein G., Wiman K. G. Infrequent MDM2 gene amplification and absence of gross WAF1 gene alterations in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol. 1995 Sep;31B(5):328–332. doi: 10.1016/0964-1955(95)00034-8. [DOI] [PubMed] [Google Scholar]
  24. Reifenberger G., Liu L., Ichimura K., Schmidt E. E., Collins V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993 Jun 15;53(12):2736–2739. [PubMed] [Google Scholar]
  25. Sheikh M. S., Shao Z. M., Hussain A., Fontana J. A. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res. 1993 Jul 15;53(14):3226–3228. [PubMed] [Google Scholar]
  26. Shibagaki I., Tanaka H., Shimada Y., Wagata T., Ikenaga M., Imamura M., Ishizaki K. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin Cancer Res. 1995 Jul;1(7):769–773. [PubMed] [Google Scholar]
  27. Takami K, Inui H, Nagayama K, Watatani M, Yasutomi M, Kurahashi H, Mori T, Takai SI, Nishisho I., I Low Grade Amplification of MDM2 Gene in a Subset of Human Breast Cancers without p53 Alterations. Breast Cancer. 1994 Dec 30;1(2):95–102. doi: 10.1007/BF02967038. [DOI] [PubMed] [Google Scholar]
  28. Waber P. G., Chen J., Nisen P. D. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res. 1993 Dec 15;53(24):6028–6030. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES